

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/G348A720088EN.html>

Date: September 2018

Pages: 72

Price: US\$ 3,500.00 (Single User License)

ID: G348A720088EN

Abstracts

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Pipeline Review, H2 2018

SUMMARY

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Myostatin also known as growth differentiation factor 8 or GDF-8 is a myokine a protein produced and released by myocytes. This protein is part of the transforming growth factor beta (TGF?) superfamily. Myostatin is found almost in muscles used for movement, where it is active both before and after birth. This protein normally restrains muscle growth, ensuring that muscles do not grow too large.

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) pipeline Target constitutes close to 13 molecules. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 4, 3 and 4 respectively. Report covers products from therapy areas Musculoskeletal Disorders, Central Nervous System, Genetic Disorders, Gastrointestinal, Hematological Disorders, Metabolic Disorders and Oncology which include indications Amyotrophic Lateral Sclerosis, Duchenne Muscular Dystrophy, Spinal Muscular Atrophy (SMA), Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Muscular Dystrophy, Sarcopenia, Anemia, Charcot-Marie-Tooth Disease, Charcot-Marie-Tooth Disease Type I, Crohn's Disease (Regional Enteritis), Insulin Resistance, Muscle Wasting Disorders, Myelodysplastic Syndrome, Myelofibrosis and Thalassemia.

The latest report GrowthDifferentiation Factor 8 Pipeline Review, H2 2018, outlays comprehensive information on the Growth/Differentiation Factor 8 (Myostatin or GDF8

or MSTN) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)

The report reviews Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics and enlists all their major and minor projects

The report assesses Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Overview

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Companies Involved in
Therapeutics Development

Accelaron Pharma Inc

Amgen Inc

Biogen Inc

Bioleaders Corp

F. Hoffmann-La Roche Ltd

PeptiDream Inc

Pfizer Inc

Regeneron Pharmaceuticals Inc

Scholar Rock Inc

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Drug Profiles

ACE-083 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ACE-2494 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALG-802 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATA-842 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIIB-110 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLS-ILB-MD1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

domagrozumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Iuspatercept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REGN-2477 + trevogrumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRK-105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit Myostatin for Duchenne Muscular Dystrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

talditercept alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trevogrumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Dormant Products

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Discontinued Products

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Product Development

Milestones

Featured News & Press Releases

Aug 31, 2018: Pfizer to abort trials of Duchenne muscular dystrophy drug

Jul 23, 2018: Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Charcot-Marie-Tooth Disease at the 2018 Annual Meeting of the Peripheral Nerve Society

Jul 12, 2018: Acceleron Receives FDA Orphan Drug Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy

Jul 09, 2018: Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III 'BELIEVE' Study in Adults with Transfusion-Dependent Beta-Thalassemia

Jul 05, 2018: Acceleron Appoints Robert K. Zeldin, M.D., Chief Medical Officer

Jun 28, 2018: Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III 'MEDALIST' Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes

Jun 26, 2018: Acceleron to Present Preliminary Data on ACE-083 at the 2018 Annual Meeting of the Peripheral Nerve Society

Jun 15, 2018: Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Beta-Thalassemia at the 23rd Congress of the European Hematology Association

Jun 04, 2018: Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the ASCO 2018 Annual Meeting

May 31, 2018: Scholar Rock Announces Completion of Dosing of First Cohort in Phase 1 Clinical Trial of SRK-015

May 17, 2018: Acceleron Announces Presentations on Luspatercept at the 23rd Congress of the European Hematology Association

May 01, 2018: Acceleron Receives FDA Fast Track Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy

Apr 26, 2018: Acceleron Announces Presentations on Lead Product Candidate Luspatercept at the 2018 American Society of Clinical Oncology Annual Meeting

Apr 26, 2018: Acceleron Announces ACE-083 Phase 2 Trial Presentation at the American Academy of Neurology 70th Annual Meeting

Apr 15, 2018: Genentech to Present Phase Ib/II Study Results of RG6206

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Acceleron Pharma Inc, H2 2018
Pipeline by Amgen Inc, H2 2018
Pipeline by Biogen Inc, H2 2018
Pipeline by Bioleaders Corp, H2 2018
Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Pipeline by PeptiDream Inc, H2 2018
Pipeline by Pfizer Inc, H2 2018
Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
Pipeline by Scholar Rock Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

Accelaron Pharma Inc

Amgen Inc

Biogen Inc

Bioleaders Corp

F. Hoffmann-La Roche Ltd

PeptiDream Inc

Pfizer Inc

Regeneron Pharmaceuticals Inc

Scholar Rock Inc

I would like to order

Product name: Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/G348A720088EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G348A720088EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970